| Contrasting forms of cocaine-evoked plasticity control components of relapse V Pascoli, J Terrier, J Espallergues, E Valjent, EC O’Connor, C Lüscher Nature 509 (7501), 459-464, 2014 | 408 | 2014 |
| Sufficiency of mesolimbic dopamine neuron stimulation for the progression to addiction V Pascoli, J Terrier, A Hiver, C Lüscher Neuron 88 (5), 1054-1066, 2015 | 293 | 2015 |
| Cell-type specific insertion of GluA2-lacking AMPARs with cocaine exposure leading to sensitization, cue-induced seeking, and incubation of craving J Terrier, C Lüscher, V Pascoli Neuropsychopharmacology 41 (7), 1779-1789, 2016 | 117 | 2016 |
| Impact of SARS‐CoV‐2 infection (COVID‐19) on cytochromes P450 activity assessed by the Geneva cocktail C Lenoir, J Terrier, Y Gloor, F Curtin, V Rollason, JA Desmeules, Y Daali, ... Clinical Pharmacology & Therapeutics 110 (5), 1358-1367, 2021 | 49 | 2021 |
| Liquid biopsy for patient characterization in cardiovascular disease: verification against markers of cytochrome P450 and P‐glycoprotein activities B Achour, P Gosselin, J Terrier, Y Gloor, ZM Al‐Majdoub, TM Polasek, ... Clinical Pharmacology & Therapeutics 111 (6), 1268-1277, 2022 | 25 | 2022 |
| Bi-directional effect of increasing doses of baclofen on reinforcement learning J Terrier, A Ort, C Yvon, A Saj, P Vuilleumier, C Lüscher Frontiers in behavioral neuroscience 5, 40, 2011 | 25 | 2011 |
| Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting C Lenoir, J Terrier, Y Gloor, P Gosselin, Y Daali, C Combescure, ... Journal of Personalized Medicine 12 (4), 526, 2022 | 24 | 2022 |
| Drug-drug interactions with direct oral anticoagulants: practical recommendations for clinicians J Terrier, F Gaspar, P Fontana, Y Daali, JL Reny, C Csajka, CF Samer The American Journal of Medicine 134 (8), 939-942, 2021 | 20 | 2021 |
| Population pharmacokinetic models for direct oral anticoagulants: a systematic review and clinical appraisal using exposure simulation J Terrier, F Gaspar, M Guidi, P Fontana, Y Daali, C Csajka, JL Reny Clinical Pharmacology & Therapeutics 112 (2), 353-363, 2022 | 7 | 2022 |
| Clinical and pharmacological considerations for concomitant administration of posaconazole and isavuconazole with letermovir J Terrier, MC Zanella, S Masouridi-Levrat, I Kronig, Y Chalandon, ... Antimicrobial Agents and Chemotherapy 65 (6), 10.1128/aac. 00274-21, 2021 | 7 | 2021 |
| Towards Personalized Antithrombotic Treatments: Focus on P2Y12 Inhibitors and Direct Oral Anticoagulants J Terrier, Y Daali, P Fontana, C Csajka, JL Reny Clinical pharmacokinetics 58, 1517-1532, 2019 | 6 | 2019 |
| Mixing drugs and genetics: a complex hemorrhagic cocktail L Barbolini, J Terrier, C Marti, C Samer, Y Daali, P Fontana, JL Reny The American Journal of Medicine 134 (3), e211-e212, 2021 | 3 | 2021 |
| Clinicians’ adherence to guidelines for the preoperative management of direct oral anticoagulants in a tertiary hospital: a retrospective study J Terrier, A Mach, P Fontana, F Bonhomme, A Casini BMC anesthesiology 23 (1), 314, 2023 | 2 | 2023 |
| Addiction par stimulation des neurones dopaminergiques mésolimbiques V Pascoli, J Terrier, C Lüscher médecine/sciences 32 (8-9), 692-696, 2016 | 2 | 2016 |
| Drug-drug interactions with oral anticoagulants: information consistency assessment of three commonly used online drug interactions databases in Switzerland C Coumau, F Gaspar, J Terrier, A Schulthess-Lisibach, M Lutters, ... Frontiers in Pharmacology 15, 1332147, 2024 | 1 | 2024 |
| Apixaban and rivaroxaban's physiologically‐based pharmacokinetic model validation in hospitalized patients: A first step for larger use of a priori modeling approach at bed side J Terrier, F Gaspar, P Gosselin, O Raboud, C Lenoir, V Rollason, ... CPT: Pharmacometrics & Systems Pharmacology 12 (12), 1872-1883, 2023 | 1 | 2023 |
| Population pharmacokinetics of apixaban in a real‐life hospitalized population from the OptimAT study F Gaspar, J Terrier, S Favre, P Gosselin, P Fontana, Y Daali, C Lenoir, ... CPT: Pharmacometrics & Systems Pharmacology 12 (10), 1541-1552, 2023 | 1 | 2023 |
| CYP450 3A4/5 containment during SARS‐CoV‐2 infection J Terrier, C Lenoir, C Samer Clinical Pharmacology and Therapeutics, 2023 | 1 | 2023 |
| Guidance on Selecting Optimal Steady-State Tacrolimus Concentrations for Continuous IV Perfusion: Insights from Physiologically Based Pharmacokinetic Modeling R Martischang, A Nikolaou, Y Daali, CF Samer, J Terrier Pharmaceuticals 17 (8), 1047, 2024 | | 2024 |
| PB0011 Evaluation of the Association between Clinical Events and Apixaban/Rivaroxaban’s Plasma exposure in Patients from the OptimAT Study J Terrier, P Gosselin, C Combescure, P Fontana, Y Daali, J Reny Research and Practice in Thrombosis and Haemostasis 7, 2023 | | 2023 |
